Long-Term Safety and Clinical Acceptability of

Shrivastava, Ram; Cohn, Cal K.; Crowder, John E.; Davidson, Jonathan; Dünner, David L.; Feighner, John P.; Kiev, Ari; Patrick, Roger

doi:10.1097/00004714-199410000-00006

Cited by 64 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, venlafaxine and dothiepin demonstrated comparable efficacy when administered to elderly patients with major depressive disorder. These results are consistent with other placebo‐controlled and comparator‐controlled studies that have shown venlafaxine to be superior or equivalent to both TCAs and SSRls for treatment of major depressive disorders 10‐13,18‐20 . While no significant differences were observed between treatments in the primary efficacy parameters, suicidal ideation scores on the MADRS showed significantly greater improvement in the venlafaxine group.…”

Section: Discussionsupporting

confidence: 89%

“…Venlafaxine is a serotonin and noradrenaline reuptake inhibitor (SNRI) and was shown to have no affinity for muscarinic cholinergic, histaminergic, or alpha‐1 adrenergic receptors in preclinical studies 8,9 . Previous clinical trials with venlafaxine have shown it to be comparable with or superior in efficacy to TCAs but with an improved safety/tolerability profile 10‐13 . In an open‐label trial, venlafaxine was well tolerated for short‐ and long‐term maintenance therapy of elderly depressed outpatients 14 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Randomised, Double‐blind, Parallel‐group Comparison of Venlafaxine and Dothiepin in Geriatric Patients With Major Depression

Hackett²

1997

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYThis randomised, double‐blind study conducted at nine sites in the UK and the Netherlands compared the safety and antidepressant efficacy of venlafaxine and dothiepin. Ninety‐two geriatric patients (aged 64‐87 years) with major depression were randomly assigned to receive either venlafaxine or dothiepin for up to 43 days. The dose of venlafaxine or dothiepin was titrated up to a maximum of 150 mg per day for the first 15 days, and thereafter could range from 50 to 150 mg per day. Adjusted mean scores on the MADRS and the HAM‐D decreased significantly (p 0.05) from baseline to the end of the study in both groups. A response to therapy was observed in 60% of patients in the venlafaxine group and 53% of patients in the dothiepin group on the MADRS, and in 60% of patients in both groups on the HAM‐D. Suicidal ideation scores on the MADRS were significantly (p=0.042) lower in the venlafaxine group at week 6. Treatment‐emergent study events were the primary reason for withdrawal in only 7% of venlafaxine‐treated patients and 8% of dothiepin‐treated patients. The results confirm the efficacy and tolerability of venlafaxine for treating major depression in the elderly.

show abstract

Section: Discussionsupporting

confidence: 89%

mentioning

confidence: 99%